Vibunazole | CAS#80456-55-9 | Antifungal

MedKoo Cat#: 526557 | Name: Vibunazole

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vibunazole is an antifungal agent

Chemical Structure

Vibunazole

CAS#80456-55-9

Theoretical Analysis

MedKoo Cat#: 526557

Name: Vibunazole

CAS#: 80456-55-9

Chemical Formula: C15H20ClN3O2

Exact Mass: 309.1244

Molecular Weight: 309.79

Elemental Analysis: C, 58.16; H, 6.51; Cl, 11.44; N, 13.56; O, 10.33

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Bay N 7133; BayN 7133; Bay-N 7133; Vibunazole

IUPAC/Chemical Name

2-((1H-1,2,4-triazol-1-yl)methyl)-1-(4-chlorophenoxy)-3,3-dimethylbutan-2-ol

InChi Key

OCQPZTCGZAFWSG-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H20ClN3O2/c1-14(2,3)15(20,8-19-11-17-10-18-19)9-21-13-6-4-12(16)5-7-13/h4-7,10-11,20H,8-9H2,1-3H3

SMILES Code

OC(COC1=CC=C(Cl)C=C1)(C(C)(C)C)CN2N=CN=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 309.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: van Gulpen C, Kelder O, Mattie H, van der Meer JW, van't Wout J. Pharmacokinetics of vibunazole (BAY n 7133) administered orally to healthy subjects. J Antimicrob Chemother. 1985 Jul;16(1):75-9. PubMed PMID: 4044466. 2: Lefler E, Stevens DA. New azole compounds: vibunazole (Bay n7133) and Bay L9139, compared with ketoconazole in the therapy of systemic candidosis and in pharmacokinetic studies, in mice. J Antimicrob Chemother. 1985 Jan;15(1):69-75. PubMed PMID: 3972759. 3: Ritter W, Plempel M. Pharmacokinetics of the oral triazole antimycotic vibunazole in animals. J Antimicrob Chemother. 1984 Sep;14(3):243-52. PubMed PMID: 6490569. 4: Odds FC, Webster CE, Abbott AB. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother. 1984 Aug;14(2):105-14. PubMed PMID: 6094418. 5: Ritter W, Holmwood G, Ahr HJ, Detzer K, Kraatz U, Plempel M, Scherling D, Siefert HM. Vibunazole and its enantiomers. Synthesis, antifungal activity, and pharmacokinetics. Ann N Y Acad Sci. 1988;544:74-85. PubMed PMID: 3063187. 6: Schaude M, Meingassner JG. A diffusion chamber technique for testing of antifungal drugs against Sporothrix schenckii in vivo. J Med Vet Mycol. 1986 Aug;24(4):297-304. PubMed PMID: 3018212. 7: Perfect JR, Durack DT. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J Antimicrob Chemother. 1985 Jul;16(1):81-6. PubMed PMID: 2995303. 8: Hiratani T, Yamaguchi H. [Cross-resistance of Candida albicans to several different families of antifungals with ergosterol biosynthesis-inhibiting activity]. Jpn J Antibiot. 1994 Feb;47(2):125-8. Japanese. PubMed PMID: 8151906. 9: Hughes CE, Beggs WH. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J Antimicrob Chemother. 1987 Feb;19(2):171-4. PubMed PMID: 3032882. 10: Okeke CN, Gugnani HC. In vitro sensitivity of environmental isolates of pathogenic dematiaceous fungi to azole compounds and a phenylpropyl-morpholine derivative. Mycopathologia. 1987 Sep;99(3):175-81. PubMed PMID: 3657909. 11: Fromtling RA, Abruzzo GK, Bulmer GS. Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC. Mycopathologia. 1986 Apr;94(1):27-30. PubMed PMID: 3014339. 12: Meunier F. Serum fungistatic and fungicidal activity in volunteers receiving antifungal agents. Eur J Clin Microbiol. 1986 Feb;5(1):103-9. PubMed PMID: 3516681. 13: Beggs WH, Hughes CE. Irrelevance of growth phase with respect to the Bay n 7133 and ICI 153,066 susceptibilities of Candida albicans. Diagn Microbiol Infect Dis. 1986 Jan;4(1):83-6. PubMed PMID: 3510807. 14: Hoeprich PD, Merry JM. Activity of BAY n 7133 and BAY 1 9139 in vitro and in experimental murine coccidioidomycosis. Eur J Clin Microbiol. 1985 Aug;4(4):400-3. PubMed PMID: 4043057. 15: Ackerbauer H, Meingassner JG, Mieth H. [Experimental renal infection with Aspergillus fumigatus in mice: a chemotherapeutic model of an organic mycosis]. Mykosen. 1985 May;28(5):244-50. German. PubMed PMID: 2989682. 16: Lefler E, Brummer E, Perlman AM, Stevens DA. Activities of the modified polyene N-D-ornithyl amphotericin methyl ester and the azoles ICI 153066, Bay n 7133, and Bay l 9139 compared with those of amphotericin B and ketoconazole in the therapy of experimental blastomycosis. Antimicrob Agents Chemother. 1985 Mar;27(3):363-6. PubMed PMID: 3994350; PubMed Central PMCID: PMC176278. 17: Lefler E, Brummer E, McEwen JG, Hoyos GL, Restrepo A, Stevens DA. Study of current and new drugs in a murine model of acute paracoccidioidomycosis. Am J Trop Med Hyg. 1985 Jan;34(1):134-40. PubMed PMID: 3970306. 18: Espinel-Ingroff A, Shadomy S, Gebhart RJ. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984 Jul;26(1):5-9. PubMed PMID: 6089654; PubMed Central PMCID: PMC179904. 19: Fromtling RA, Yu HP, Shadomy S. In vitro antifungal activities of Bay n 7133 and Bay L 9139, two new orally absorbed antifungal imidazole derivatives, against pathogenic yeasts. Mycopathologia. 1984 Apr 30;86(1):45-50. PubMed PMID: 6330557. 20: Nusch W, Plempel M. [Microbiological determination of the oral antifungal agent Bay N 7133 and ketoconazole in cervical and vaginal secretion of patients]. Mykosen. 1983 Dec;26(12):600-4. German. PubMed PMID: 6319990.